Borui Pharmaceuticals (688166.SH) released its semi-annual performance, with a net profit attributable to the parent company of 17.17 million yuan, a year-on-year decrease of 83.85%.

Smart Finance and Economics APP News, Borui Medicine (688166.SH) disclosed its semi-annual report for the year 2025. During the reporting period, the company achieved a revenue of 537 million yuan, a year-on-year decrease of 18.28%; net profit attributable to shareholders was 17.17 million yuan, a year-on-year decrease of 83.85%; non-GAAP net profit was 14.37 million yuan, a year-on-year decrease of 86.35%; and basic earnings per share was 0.04 yuan.